Marcan buys remaining Mantra Pharma preferred shares for CAD 50 million

Listed Co AcquisitionStrategic Transactions View source PDF Explain this filing

EMCURE · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-0.7%Reaction day

₹1859.00

prior close

₹1844.60

announcement price

In-mkt

timing

Nifty Smallcap 250market+0.1%-0.7% vs market

Pharmaceuticals peers, median of 165sector+0.2%-0.9% vs sector

On the reaction day the stock moved 0.7 pts less than Nifty Smallcap 250 and 0.9 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.0

10m

+0.2

15m

+0.0

30m

+0.2

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-0.7+0.1-0.7+0.2-0.9

Next day

-1.3+0.5-1.8-0.3-1.0

-0.8-0.2-0.6-0.5-0.3

-2.6-2.1-0.4-1.2-1.4

-2.7-0.6-2.1-0.6-2.1

-2.6+0.8-3.4-0.1-2.6

-2.5-0.0-2.5+0.6-3.1

15d

+1.3-2.1+3.4-1.9+3.2

+5.3+1.0+4.3-0.8+6.0

+0.0+2.6-2.5+0.9-0.9

+4.2-1.8+6.0+0.3+3.9

UpDownMarket · Nifty Smallcap 250Sector · Pharmaceuticals peers, median of 165Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Marcan Pharmaceuticals Inc, Emcure's subsidiary, signed agreements on July 2, 2026 to acquire all Class E Special Shares in Mantra Pharma Inc, its Canadian step-down subsidiary, for CAD 50 million cash. Mantra remains 100 percent owned by Marcan after the deal. Mantra distributes prescription drugs and natural health products in Canada, with FY26 turnover of CAD 96.67 million versus CAD 81.01 million in FY25. It is a related party transaction between wholly-owned subsidiaries, done at arms length, expected to complete on July 3, 2026.

Likely market impact

Internal consolidation of 100 percent ownership in Mantra Pharma, a growing Canadian distribution arm; no change in overall group control.